Sign in Subscribe
Machine learning

Breakthrough Blood Test Shows Promise in Detecting Ovarian Cancer at Early Stages

Strategic Insights

— 2 min read

Researchers have made a groundbreaking discovery in the development of a blood test that can accurately detect ovarian cancer at its earliest stages, potentially transforming the way the disease is diagnosed and treated. The innovative test, created by AOA Dx, uses machine learning to identify two distinct blood markers in individuals presenting with symptoms such as pelvic pain and bloating. This test has shown remarkable accuracy in detecting ovarian cancer across various stages of the disease, with 93% accuracy at all stages and 91% in early stages in a study of 832 samples.

Key Takeaways:

  • The AOA Dx blood test uses machine learning to identify distinct blood markers in individuals presenting with symptoms of ovarian cancer, such as pelvic pain and bloating.
  • The test has shown remarkable accuracy in detecting ovarian cancer across various stages of the disease, with 93% accuracy at all stages and 91% in early stages in a study of 832 samples.
  • The test can detect the disease "at early stages and with greater accuracy than current tools", according to Alex Fisher, chief operating officer and co-founder of AOA Dx.
  • Dr Abigail McElhinny, chief science officer of AOA Dx, stated that the test's platform offers a great opportunity to improve the early diagnosis of ovarian cancer, potentially resulting in better patient outcomes and lower costs to the healthcare system.
  • A study led by researchers at the universities of Manchester and Colorado, published in the American Association of Cancer Research (AACR) journal Cancer Research Communications, tested 832 samples using the AOA Dx platform.
  • Emma Crosbie, a professor at the University of Manchester and honorary consultant in gynaecological oncology at Manchester University NHS Foundation Trust (MFT), expressed enthusiasm for the platform's potential to significantly improve patient care and outcomes for women diagnosed with ovarian cancer.

Statistics:

  • Annual incidence of ovarian cancer in the UK: approximately 7,500 cases
  • Predominant age group affected by ovarian cancer: over 50 years old
  • Symptoms of ovarian cancer: persistent pain in the abdomen or pelvis, feeling full quickly after eating, peeing frequently, and bloating
  • Accuracy of the AOA Dx test in detecting ovarian cancer at all stages: 93%
  • Accuracy of the AOA Dx test in detecting ovarian cancer in early stages: 91%
  • Number of patient samples tested in the study: 832

Sources:

  • AOA Dx, "Breakthrough Blood Test Detects Ovarian Cancer at Early Stages"
  • American Association of Cancer Research (AACR), Cancer Research Communications, "Detection of Ovarian Cancer using a Novel Machine Learning-Based Platform"
  • University of Manchester, "AOA Dx's Platform Has the Potential to Significantly Improve Patient Care and Outcomes for Women Diagnosed with Ovarian Cancer"

Read more